Natalie S. Callander, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Callander joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander has completed residency at Bellevue Hospital in New York and a Hematology/Oncology fellowship at the University of California-San Diego.
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of California, San Diego
Bellevue Hospital, New York
Bellevue Hospital, New York, NY
Tufts University School of Medicine, Boston, MA, 1985
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
Her clinical and research interests include: inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma.
Callander N Markovina S Eickhoff J Hutson P Campbell T Hematti P Go R Hegeman R Longo W Williams E Asimakopoulos F Miyamoto S .
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Aug 29;
[PubMed ID: 25168296]
Sharma M Zhang MJ Zhong X Abidi MH Akpek G Bacher U Callander NS Dispenzieri A Freytes CO Fung HC Gale RP Gasparetto C Gibson J Holmberg LA Kindwall-Keller TL Klumpp TR Krishnan AY Landau HJ Lazarus HM Lonial S Maiolino A Marks DI Mehta P Mikhael Med JR Nishihori T Olsson R Ramanathan M Roy V Savani BN Schouten HC Scott E Tay J To LB Vesole DH Vogl DT Hari P .
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biol Blood Marrow Transplant. 2014 Jul 18;
[PubMed ID: 25046833]
Hope C Ollar SJ Heninger E Hebron E Jensen JL Kim J Maroulakou I Miyamoto S Leith C Yang DT Callander N Hematti P Chesi M Bergsagel PL Asimakopoulos F .
TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22;123(21):3305-15
[PubMed ID: 24723682]
Asimakopoulos F Kim J Denu RA Hope C Jensen JL Ollar SJ Hebron E Flanagan C Callander N Hematti P .
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Oct;54(10):2112-21
[PubMed ID: 23432691]
Hebron E Hope C Kim J Jensen JL Flanagan C Bhatia N Maroulakou I Mitsiades C Miyamoto S Callander N Hematti P Asimakopoulos F .
MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar;160(6):779-84
[PubMed ID: 23252623]
Kim J Denu RA Dollar BA Escalante LE Kuether JP Callander NS Asimakopoulos F Hematti P .
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug;158(3):336-46
[PubMed ID: 22583117]
Young EW Pak C Kahl BS Yang DT Callander NS Miyamoto S Beebe DJ .
Microscale functional cytomics for studying hematologic cancers. Blood. 2012 Mar 8;119(10):e76-85
[PubMed ID: 22262772]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS .
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Markovina S Callander NS O'Connor SL Xu G Shi Y Leith CP Kim K Trivedi P Kim J Hematti P Miyamoto S .
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010 Jul 6;9:176
[PubMed ID: 20604947]
Markovina S Callander NS O'Connor SL Kim J Werndli JE Raschko M Leith CP Kahl BS Kim K Miyamoto S .
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356-64
[PubMed ID: 18708367]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL .
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]